Prognostic Significance of Blood Transfusion in Elderly Patients with Primary Diffuse Large B-Cell Lymphoma

Table 1

Characteristics of elderly DLBCL patients who did and did not receive blood transfusions.

Characteristic		Transfused	Nontransfused
		() (%)	() (%)
Age, years	Mean	68.42 ± 0.90	68.74 ± 0.74	0.8246
Gender	Male	15 (62.5)	50 (62.5)	1.000
	Female	9 (37.5)	30 (37.5)
Ann Arbor staging	I-II	7 (29.2)	29 (36.3)	0.6282
	III-IV	17 (70.8)	51 (63.7)
Extranodular involvement	Yes	8 (33.3)	33 (41.3)	0.6348
	No	16 (66.7)	47 (58.7)
Bone marrow involvement	Yes	1 (4.2)	2 (2.5)	0.5488
	No	23 (95.8)	78 (97.5)
B symptoms	Yes	6 (25.0)	7 (8.8)	0.0708
	No	18 (75.0)	73 (91.2)
LDH (IU/L)	≥245	15 (62.5)	27 (33.8)	0.0172
	<245	9 (37.5)	53 (66.2)
IPI	0–2	8 (33.3)	37 (46.3)	0.3487
	3–5	16 (66.7)	43 (53.7)
Cell of origin	GCB	5 (20.8)	32 (40.0)	0.0955
	Non-GCB	19 (79.2)	48 (60.0)
Plt	≥100 × 10^9/L	20 (83.3)	77 (96.2)	0.0479
	<100 × 10^9/L	4 (16.7)	3 (3.8)
Hb (g/L)	≥100	12 (50.0)	73 (91.2)	<0.0001
	<100	12 (50.0)	7 (8.8)
Alb (g/L)	≥35	8 (33.3)	59 (73.8)	0.0005
	<35	16 (66.7)	21 (26.2)
Rituximab	Yes	14 (58.3)	56 (70.0)	0.3255
	No	10 (41.7)	24 (30.0)

LDH: lactate dehydrogenase; IPI: International Prognostic Index; Hb: hemoglobin; Alb: albumin.